T M Kuijper1,2, J J Luime2, P H P de Jong1, A H Gerards3, D van Zeben4, I Tchetverikov5, P B J de Sonnaville6,7, M V van Krugten6,8, B A Grillet9,10,11, J M W Hazes2, A E A M Weel1,2. 1. Department of Rheumatology, Maasstad Hospital, Rotterdam, The Netherlands. 2. Department of Rheumatology, Erasmus MC University Medical Center, Rotterdam, The Netherlands. 3. Department of Rheumatology, Vlietland Hospital, Schiedam, The Netherlands. 4. Department of Rheumatology, Sint Franciscus Gasthuis, Rotterdam, The Netherlands. 5. Department of Rheumatology, Albert Schweitzer Hospital, Dordrecht, The Netherlands. 6. Department of Rheumatology, Admiraal de Ruyter Hospital, Goes, The Netherlands. 7. Reumazorg Zuid West Nederland, Goes, The Netherlands. 8. Reumazorg Zuid West Nederland, Vlissingen, The Netherlands. 9. Department of Rheumatology, Admiraal de Ruyter Hospital, Vlissingen, The Netherlands. 10. Department of Rheumatology, ZorgSaam Hospital, Terneuzen, The Netherlands. 11. Reumazorg Zuid West Nederland, Terneuzen, The Netherlands.
Abstract
OBJECTIVES: With early and intensive treatment many patients with early RA attain remission. Aims were to investigate (1) the frequency and time to sustained remission and subsequent tapering in patients initially treated with conventional synthetic disease modifying anti-rheumatic drug ((cs)DMARD) strategies and (2) the frequency and time to flare and regained remission in patients tapering csDMARDs and biological (b)DMARDs during 2 years of follow-up. METHODS: Two-year follow-up data from the treatment in the Rotterdam Early Arthritis Cohort (tREACH) cohort were used. Patients were randomised to initial treatment with triple DMARD therapy (iTDT) with glucocorticoid (GC) bridging or methotrexate monotherapy (iMM) with GC bridging. Patients were evaluated every 3 months. In case Disease Activity Score (DAS) was >2.4 treatment was switched to a TNF-blocker. In case DAS<1.6 at 2 consecutive time points, tapering was initiated according to protocol. Outcomes were rates of sustained remission (DAS<1.6 at 2 consecutive time points), flare (medication increase after tapering) and remission after flare (DAS<1.6). Data were analysed using Kaplan-Meier analyses. RESULTS: During 2 years of follow-up, sustained remission was achieved at least once by 159 (57%) of patients, of whom 118 and 23 patients initiated tapering of csDMARDs and bDMARDs, respectively. Thirty-four patients achieved drug-free remission. Flare rates were 41% and 37% and within 1 year, respectively. After flare, 65% of patients tapering csDMARDs re-achieved remission within 6 months after treatment intensification. CONCLUSIONS: Regardless of initial treatment strategy, 57% of patients achieved sustained remission during 2 years of follow-up. Flare rates were 41% and 37% within 12 months in patients tapering csDMARDs and bDMARDs, respectively. TRIAL REGISTRATION NUMBER: ISRCTN26791028; Post-results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
RCT Entities:
OBJECTIVES: With early and intensive treatment many patients with early RA attain remission. Aims were to investigate (1) the frequency and time to sustained remission and subsequent tapering in patients initially treated with conventional synthetic disease modifying anti-rheumatic drug ((cs)DMARD) strategies and (2) the frequency and time to flare and regained remission in patients tapering csDMARDs and biological (b)DMARDs during 2 years of follow-up. METHODS: Two-year follow-up data from the treatment in the Rotterdam Early Arthritis Cohort (tREACH) cohort were used. Patients were randomised to initial treatment with triple DMARD therapy (iTDT) with glucocorticoid (GC) bridging or methotrexate monotherapy (iMM) with GC bridging. Patients were evaluated every 3 months. In case Disease Activity Score (DAS) was >2.4 treatment was switched to a TNF-blocker. In case DAS<1.6 at 2 consecutive time points, tapering was initiated according to protocol. Outcomes were rates of sustained remission (DAS<1.6 at 2 consecutive time points), flare (medication increase after tapering) and remission after flare (DAS<1.6). Data were analysed using Kaplan-Meier analyses. RESULTS: During 2 years of follow-up, sustained remission was achieved at least once by 159 (57%) of patients, of whom 118 and 23 patients initiated tapering of csDMARDs and bDMARDs, respectively. Thirty-four patients achieved drug-free remission. Flare rates were 41% and 37% and within 1 year, respectively. After flare, 65% of patients tapering csDMARDs re-achieved remission within 6 months after treatment intensification. CONCLUSIONS: Regardless of initial treatment strategy, 57% of patients achieved sustained remission during 2 years of follow-up. Flare rates were 41% and 37% within 12 months in patients tapering csDMARDs and bDMARDs, respectively. TRIAL REGISTRATION NUMBER: ISRCTN26791028; Post-results. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://www.bmj.com/company/products-services/rights-and-licensing/.
Authors: Siri Lillegraven; Nina Paulshus Sundlisæter; Anna-Birgitte Aga; Joseph Sexton; Inge C Olsen; Hallvard Fremstad; Cristina Spada; Tor Magne Madland; Christian A Høili; Gunnstein Bakland; Åse Lexberg; Inger Johanne Widding Hansen; Inger Myrnes Hansen; Hilde Haukeland; Maud-Kristine Aga Ljoså; Ellen Moholt; Till Uhlig; Daniel H Solomon; Désirée van der Heijde; Tore K Kvien; Espen A Haavardsholm Journal: JAMA Date: 2021-05-04 Impact factor: 56.272
Authors: Kenneth F Baker; Andrew J Skelton; Dennis W Lendrem; Adam Scadeng; Ben Thompson; Arthur G Pratt; John D Isaacs Journal: J Autoimmun Date: 2019-07-04 Impact factor: 14.511
Authors: M Verstappen; E Niemantsverdriet; X M E Matthijssen; S le Cessie; A H M van der Helm-van Mil Journal: Arthritis Res Ther Date: 2020-11-23 Impact factor: 5.156
Authors: Irazú Contreras-Yáñez; Guillermo Arturo Guaracha-Basáñez; Maximiliano Cuevas-Montoya; José de Jesús Hernández-Bautista; Virginia Pascual-Ramos Journal: Arthritis Res Ther Date: 2022-08-12 Impact factor: 5.606